Skip navigation

Why big pharma sees a remedy in data and AI

BERG is pleased to share the Financial Times feature by Global Pharmaceuticals Editor, Sarah Neville, “Why big pharma sees a remedy in data and AI”, that  includes commentary from Dr. Niven R. Narain, President and CEO of BERG along with notable leaders from the likes of Novartis, Pfizer and Flatiron Health.

The article highlights the importance of taking a balanced view of the opportunity for drug development using the vastly unutilized data from anonymized patient records. By combining this Real World Evidence (RWE) with AI, the chances of uncovering personalized therapies grows higher. However, the hype around AI and medicine is to be taken cautiously. Recognizing the underlying biology of the disease is key to yielding insights into drug development. Overall, it is underscores AI as a tool to unravel patient biology to accelerate development and lower costs in drug development.

Learn more.